Zynerba Pharmaceuticals Inc

NASDAQ:ZYNE  
4.50
+0.49 (+12.22%)
Products

Zynerba Says Meeting With FDA Planned For Q4 To Discuss Regulatory Path Forward For Zygel

Published: 09/14/2020 11:12 GMT
Zynerba Pharmaceuticals Inc (ZYNE) - Zynerba Pharmaceuticals Provides Update on Recent Milestones.
Zynerba Pharmaceuticals Inc - FDA Suggests Pursuing Individual Syndromes in Developmental and Epileptic Encephalopathies Program.
Zynerba Pharmaceuticals Inc - Meeting With FDA Planned for 4q2020 to Discuss Regulatory Path Forward for Zygel.
Zynerba Pharmaceuticals Inc - Company is in Process of Finalizing Its Evaluation of Which Epileptic Syndromes It May Pursue With Zygel.